Q-omics provides the consensus-scored MIR212 profile across patient tissues and cancer cell-line models. MIR212 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR212 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MIR212 RNA expression shows 3,864 significant pathway-activity associations, with the highest sampling consensus in OV. Together, these results highlight UVM, LUSC, and OV as cancer lineages where MIR212 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR212 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR212 survival associations across molecular data types. MIR212 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR212 RNA expression–survival associations across cancer types. High MIR212 expression shows unfavorable associations in UVM, LUSC, UCEC, KIRC and BLCA, but favorable associations in STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR212 RNA expression.
This table summarizes MIR212 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR212. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR212 shows lower tumor expression in LUSC. The LUSC box plot shows higher MIR212 RNA expression in normal versus tumor tissue (log2 FC = −0.042, t-test p = .046).
This table shows molecular features associated with MIR212 in patient tissues and cancer cell lines. In patient samples, MIR212 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
